Program Content


  • EZH1/2 Inhibitors in PTCL
    Rationale and Evidence for EZH1/2 Inhibitors in PTCL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 08, 2022

    Expires: August 07, 2023


cover img faculity

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

cover img faculity

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

cover img faculity

Pierluigi Porcu, MD

Professor and Director
Division of Hematology Malignancies
Department of Medical Oncology
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

ProCE Banner


Daiichi Sankyo, Inc.